Broad spectrum post-entry inhibitors of coronavirus replication : Cardiotonic steroids and monensin
Crown Copyright © 2023. Published by Elsevier Inc. All rights reserved..
A small molecule screen identified several cardiotonic steroids (digitoxin and ouabain) and the ionophore monensin as potent inhibitors of HCoV-229E, HCoV-OC43, and SARS-CoV-2 replication with EC50s in the low nM range. Subsequent tests confirmed antiviral activity in primary cell models including human nasal epithelial cells and lung organoids. Addition of digitoxin, ouabain, or monensin strongly reduced viral gene expression as measured by both viral protein and RNA accumulation. Furthermore, the compounds acted post virus entry. While the antiviral activity of digitoxin was dependent upon activation of the MEK and JNK signaling pathways but not signaling through GPCRs, the antiviral effect of monensin was reversed upon inhibition of several signaling pathways. Together, the data demonstrates the potent anti-coronavirus properties of two classes of FDA approved drugs that function by altering the properties of the infected cell, rendering it unable to support virus replication.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:589 |
|---|---|
| Enthalten in: |
Virology - 589(2023) vom: 15. Jan., Seite 109915 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jahanshahi, Shahrzad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
5ACL011P69 |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 16.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.virol.2023.109915 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364233982 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364233982 | ||
| 003 | DE-627 | ||
| 005 | 20231227133149.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.virol.2023.109915 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1230.xml |
| 035 | |a (DE-627)NLM364233982 | ||
| 035 | |a (NLM)37931588 | ||
| 035 | |a (PII)S0042-6822(23)00234-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jahanshahi, Shahrzad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Broad spectrum post-entry inhibitors of coronavirus replication |b Cardiotonic steroids and monensin |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 16.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Crown Copyright © 2023. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a A small molecule screen identified several cardiotonic steroids (digitoxin and ouabain) and the ionophore monensin as potent inhibitors of HCoV-229E, HCoV-OC43, and SARS-CoV-2 replication with EC50s in the low nM range. Subsequent tests confirmed antiviral activity in primary cell models including human nasal epithelial cells and lung organoids. Addition of digitoxin, ouabain, or monensin strongly reduced viral gene expression as measured by both viral protein and RNA accumulation. Furthermore, the compounds acted post virus entry. While the antiviral activity of digitoxin was dependent upon activation of the MEK and JNK signaling pathways but not signaling through GPCRs, the antiviral effect of monensin was reversed upon inhibition of several signaling pathways. Together, the data demonstrates the potent anti-coronavirus properties of two classes of FDA approved drugs that function by altering the properties of the infected cell, rendering it unable to support virus replication | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cardiotonic steroids | |
| 650 | 4 | |a Coronavirus | |
| 650 | 4 | |a Monensin | |
| 650 | 4 | |a Pan antiviral | |
| 650 | 7 | |a Cardiac Glycosides |2 NLM | |
| 650 | 7 | |a Monensin |2 NLM | |
| 650 | 7 | |a 906O0YJ6ZP |2 NLM | |
| 650 | 7 | |a Ouabain |2 NLM | |
| 650 | 7 | |a 5ACL011P69 |2 NLM | |
| 650 | 7 | |a Digitoxin |2 NLM | |
| 650 | 7 | |a E90NZP2L9U |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Ouyang, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Choudhary |e verfasserin |4 aut | |
| 700 | 1 | |a Zahedi Amiri, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Dahal, Subha |e verfasserin |4 aut | |
| 700 | 1 | |a Mao, Yu-Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Van Ommen, David A J |e verfasserin |4 aut | |
| 700 | 1 | |a Malty, Ramy |e verfasserin |4 aut | |
| 700 | 1 | |a Duan, Wenming |e verfasserin |4 aut | |
| 700 | 1 | |a Been, Terek |e verfasserin |4 aut | |
| 700 | 1 | |a Hernandez, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Mangos, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Nurtanto, Jocelyn |e verfasserin |4 aut | |
| 700 | 1 | |a Babu, Mohan |e verfasserin |4 aut | |
| 700 | 1 | |a Attisano, Liliana |e verfasserin |4 aut | |
| 700 | 1 | |a Houry, Walid A |e verfasserin |4 aut | |
| 700 | 1 | |a Moraes, Theo J |e verfasserin |4 aut | |
| 700 | 1 | |a Cochrane, Alan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Virology |d 1955 |g 589(2023) vom: 15. Jan., Seite 109915 |w (DE-627)NLM000011347 |x 1096-0341 |7 nnns |
| 773 | 1 | 8 | |g volume:589 |g year:2023 |g day:15 |g month:01 |g pages:109915 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.virol.2023.109915 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 589 |j 2023 |b 15 |c 01 |h 109915 | ||